Larimar Therapeutics, Inc. (LRMR) Key Metrics
LRMR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $206.2M
- Enterprise value
- $250.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.2 10-yr median 1.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.69
LRMR key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLRMR valuation Price multiples at each fiscal year-end price.
LRMR returns How much profit the business earns on the capital it uses.
LRMR per-share figures Results divided by the shares outstanding at year-end.
LRMR financial health Debt, liquidity and how easily interest is covered.
LRMR efficiency & capital use Working capital cycle and where the cash goes.
LRMR valuation history
LRMR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LRMR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LRMR price vs earnings per share
LRMR key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $277.9M | $237.1M | $199.8M | $106.4M | — | — | — | — | — | — |
| Enterprise value | $145.1M | $58.7M | $118.5M | −$6.6M | — | — | — | — | — | — |
| Price / book | 3.6 | 1.4 | 2.4 | 1.0 | — | — | — | — | — | — |
| Earnings yield | −59.6% | −34.0% | −18.5% | −32.1% | — | — | — | — | — | — |
| Free cash flow yield | −40.8% | −30.1% | −16.8% | −26.0% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $3.81 | $3.87 | $4.55 | $4.13 | $10.79 | $21.41 | $13.32 | $59.40 | $55.44 | $38.16 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$2.27 | −$1.32 | −$0.84 | −$1.33 | — | — | — | — | — | — |
| Operating cash flow per share | −$1.55 | −$1.16 | −$0.76 | −$1.07 | — | — | — | — | — | — |
| Free cash flow per share | −$1.55 | −$1.16 | −$0.77 | −$1.07 | — | — | — | — | — | — |
| Cash per share | $1.88 | $2.99 | $1.98 | $4.60 | — | — | — | — | — | — |
| Book value per share | $1.07 | $2.80 | $1.86 | $4.31 | — | — | — | — | — | — |
| Tangible book value per share | $1.07 | $2.80 | $1.86 | $4.31 | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.01 | $0.00 | $0.00 | — | — | — | — | — | — |
| Debt per share | $0.06 | $0.08 | $0.13 | $0.21 | — | — | — | — | — | — |
| Shares outstanding | 72.9M | 61.3M | 43.9M | 25.8M | — | — | — | — | — | — |
| Change in shares outstanding | +19.1% | +39.5% | +70.4% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −132.6% | −63.6% | −38.4% | −39.0% | −65.3% | −95.1% | — | −71.6% | −52.0% | −39.8% |
| Return on invested capital (ROIC) | — | — | — | — | — | −648.5% | — | — | — | — |
| Return on assets (ROA) | −95.7% | −54.4% | −33.2% | −33.3% | −54.9% | −77.0% | −36.4% | −54.0% | −43.9% | −36.1% |
| Return on tangible assets | −113.6% | −40.3% | −38.5% | −27.0% | −64.0% | −40.4% | −444.8% | −50.4% | −49.3% | −44.0% |
| Financial health | ||||||||||
| Total debt | $4.1M | $5.1M | $5.5M | $5.4M | $6.0M | $6.5M | $8.6M | $20.6M | $20.0M | $3.6M |
| Cash & short-term investments | $136.9M | $183.5M | $86.8M | $118.4M | $70.1M | $92.6M | $1.0M | $118.1M | $102.1M | $129.2M |
| Net debt | −$132.8M | −$178.3M | −$81.2M | −$113.0M | −$64.1M | −$86.1M | $7.6M | −$97.4M | −$82.1M | −$125.6M |
| Debt / equity | 0.05 | 0.03 | 0.07 | 0.05 | 0.09 | 0.07 | — | 0.22 | 0.26 | 0.03 |
| Debt / assets | 0.03 | 0.03 | 0.06 | 0.04 | 0.08 | 0.06 | 1.65 | 0.17 | 0.19 | 0.03 |
| Current ratio | 2.19 | 8.02 | 9.49 | 11.28 | 8.16 | 10.89 | 0.81 | 9.12 | 14.39 | 13.23 |
| Quick ratio | 2.19 | 8.02 | 9.49 | 11.28 | 8.19 | 10.90 | 0.27 | 9.12 | 14.39 | 13.23 |
| Interest coverage | — | — | — | -114.9 | -154.8 | — | -13.1 | -255.0 | -55.5 | -164.6 |
| Working capital | $77.2M | $170.9M | $80.7M | $110.0M | $63.4M | $89.0M | −$1.1M | $108.0M | $97.6M | $121.0M |
| Invested capital | −$54.7M | −$6.5M | $476,000 | −$2.1M | $318,000 | $3.6M | $6.9M | −$4.2M | −$3.8M | −$3.9M |
| Tangible asset value | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M | $89.7M | −$694,000 | $93.3M | $78.2M | $121.7M |
| Net current asset value | $74.3M | $166.9M | $76.0M | $105.2M | $58.0M | $83.0M | −$1.1M | $92.8M | $77.6M | $121.0M |
| Graham net-net per share | $0.95 | $2.54 | $1.66 | $4.00 | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | 0.26 | 1.62 | 0.53 | 0.31 | 1.02 | 0.40 | 1.06 | 0.41 | 0.29 | 3.11 |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | — | — | -134.4 | 3,687.7 | 14,805.9 | — | — | 0.0 |
| Days payables outstanding | 3,983.7 | 2,127.4 | 1,742.3 | 2,245.0 | 2,403.8 | 7,268.2 | 10,407.2 | 2,747.3 | 5,428.4 | 8,666.2 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.09 | 0.17 | 0.21 | 0.16 | 0.15 | 0.05 | 0.04 | 0.13 | 0.07 | 0.04 |
| Inventory turnover | — | — | — | — | — | — | 0.02 | — | — | 212,000.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $900,500 | $693,000 | $332,000 | — | $120,000 | $95,000 | $847,000 | $1.2M | $646,500 | $835,000 |
| Average payables | $3.8M | $1.9M | $1.5M | $1.7M | $2.1M | $3.1M | $2.2M | $2.0M | $2.8M | $5.0M |
| Average inventory | — | — | — | — | −$120,000 | $1.6M | $3.2M | — | — | $1 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from LRMR's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LRMR valuation and financial ratios
Larimar Therapeutics earned a return on equity of −132.6% in fiscal 2025. It ended the year with $4.1 million of debt and $136.9 million in cash and short-term investments, a net cash position of $132.8 million.
See the LRMR income statement, the LRMR chart for price history, or the LRMR stock overview for the latest quote and news.
LRMR key metrics FAQ
What is Larimar Therapeutics's return on equity?
Larimar Therapeutics's return on equity (ROE) was −132.6% in fiscal 2025: net income of -$165.7 million on average shareholders' equity of $124.9 million.
How much debt does Larimar Therapeutics have?
Larimar Therapeutics had total debt of $4.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Larimar Therapeutics's free cash flow yield?
Larimar Therapeutics generated -$113.3 million of free cash flow in fiscal 2025, a free cash flow yield of −40.8% on its market value at year-end ($277.9 million).
What is Larimar Therapeutics's current ratio?
Larimar Therapeutics's current ratio was 2.19 at the end of fiscal 2025: current assets were 2.19 times current liabilities.